生物瓣全人工心脏作为移植桥接:EFICAS 研究
生物瓣全人工心脏植入后 180 天无致残性卒中、无装置故障需再手术或紧急移植、或择期心脏移植的生存率为 72.7%。该结果超过预设的历史全人工心脏阈值 38%,支持其作为有效移植桥接策略。
要点
- 生物瓣全人工心脏 180 天主要复合终点达标率 72.7%,超过预设阈值 38%
- 180 天时 96% 无致残性卒中,无溶血发生,大出血仅限于术后 30 天内
- 适用于不适合 LVAD 支持的难治性晚期双心室心力衰竭患者的移植桥接
核心结论
- 生物瓣全人工心脏达到主要终点且安全性良好,支持其作为不适合 LVAD 支持的难治性晚期双心室心力衰竭患者的有效移植桥接策略。
研究设计与样本
- EFICAS(NCT04475393)为前瞻性多中心试验,在法国 10 家中心开展。
主要发现
- 主要复合终点在 40 例患者中达标,达标率为 72.7%(95% CI 57.1-85.1),超过预设历史全人工心脏阈值 38%(p<0.0001)。
- 180 天时 96% 无致残性卒中,76% 出院,92% 为 NYHA I-II 级。
- 6 分钟步行距离中位改善 305 米(p=0.0002),EQ-5D 改善 40 分(p<0.0001)。
- 无溶血发生,大出血仅限于术后 30 天内。
关键数值与推荐
- 主要复合终点为 180 天生存且无致残性卒中、无装置故障需再手术或紧急移植、或择期心脏移植。
- 预设的历史全人工心脏达标阈值为 38%。
- 主要终点达标率 72.7%(95% CI 57.1-85.1,p<0.0001)。
临床怎么用
- 对于不适合 LVAD 支持的难治性晚期双心室心力衰竭患者,可考虑使用生物瓣全人工心脏作为移植桥接。
- 关注术后 30 天内的大出血风险,之后安全性特征较为有利。
局限性
- 原文未报告对照组设置及长期随访数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Refractory advanced biventricular heart failure (RAHF) has a poor prognosis, and many patients are ineligible for left ventricular assist device (LVAD) support. The "historical" total artificial heart (TAH) is associated with high rates of stroke, bleeding, and haemolysis. The bioprosthetic TAH (bio-TAH), a pulsatile, autoregulated, and haemocompatible device, was assessed here as a bridge to transplantation. METHODS: EFICAS (NCT04475393) was a prospective, multicentre trial conducted at 10 French centres. Adults with RAHF who were ineligible for LVAD support and listed or eligible for heart transplantation were enrolled. The primary composite endpoint was survival at 180 days free from disabling stroke, device malfunction requiring reoperation or urgent transplantation, or elective heart transplantation. Secondary endpoints included serious adverse events, NYHA class, the 6-min walk test, and quality of life measured using the EQ-5D-5L. RESULTS: Fifty-five patients underwent implantation (December 2022 and May 2025; median age, 56 years [IQR, 48-63]; 49% INTERMACS profiles 1-2; 36% on VA-ECMO). The primary endpoint was achieved in 40 patients (72.7%; 95% confidence interval, 57.1-85.1), exceeding the prespecified "historical TAH" threshold of 38% (p<0.0001). At 180 days, 96% were free of disabling stroke, 76% were discharged, and 92% were NYHA class I-II. Median 6-minute walk distance improved by 305 m (p=0.0002) and EQ-5D by 40 points (p<0.0001). No haemolysis occurred, and major bleeding was limited to the first 30 days. CONCLUSIONS: The bio-TAH achieved its primary endpoint with a favourable safety profile, supporting its use as an effective bridge-to-transplant strategy in patients with RAHF ineligible for LVAD support.
引用
- Vincentelli, Martin, Guihaire, et al. Auto-regulated bioprosthetic total artificial heart as bridge to transplantation: the EFICAS study. Eur Heart J. 2026. PMID: 42670784. doi:10.1093/eurheartj/ehag704
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。